Pfizer Rare Disease Leaders: An Interview With “The Pink Sheet” DAILY
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer’s rare disease commercial unit head Andrew Callos and research unit chief scientific officer Kevin Lee outline how the company’s rare disease business has grown since formed in 2010, discuss why the Big Pharma’s interest in drugs for rare diseases is here to stay and consider what’s next for the portfolio on the business development front.